R&D Directions’ March Issue Profiles 100 Great Investigational Drugs, Talks with Pfizer’s President of Global Research & Development, and More
NEWTOWN, PA, March 29, 2007 –
R&D Directions
announces publication of its March issue. In this issue, R&D Directions profiles 100
investigational drugs and reviews hundreds of others from Phase I
through Phase III.
Currently, thousands of compounds are being developed at large and
small companies throughout the world. To be included in R&D Directions’ top 100
list, substances had to show potential in a major or growing
therapeutic area and be active in development. Many of the
compounds on the list address unmet medical needs. Five of the top
100 great investigational drugs are being developed by Pfizer
Inc.
Also in this issue, R&D
Directions’ managing editor, Lyle D. Fitzsimmons, talks
with Pfizer’s president of global research and development,
Dr. John LaMattina, about the specific challenges Pfizer faces as
the biggest R&D spender in the industry. LaMattina states,
“Pfizer is an A-list celebrity in its field, and we’ve
learned to thrive under intense scrutiny.”
Other featured articles in the March issue include, “Secrets
for success: Helpful hints for successful clinical
investigations,” in which Dr. Mark H. Gotfried, Medical
Director at PACT, shares his secrets for long-term success in
clinical investigations. Editor Joseph Gialanella discusses
strategic changes abroad for Eli Lilly and Co. in “Lilly
changes its ways.” Gialanella also presents “A cardiac
pact,” explaining a multi-year research alliance between
Pfizer and iCardiac Technologies Inc. to develop and validate
advanced cardiac safety biomarkers.
About R&D
Directions
R&D Directions provides a one-of-a-kind perspective on the
business of pharmaceutical research and development, from discovery
through clinical trials and submission. Leaving the hard science to
other publications, R&D
Directions focuses on pharmaceutical companies’ R&D
business strategies and decisions. More than 12,000 readers –
comprising senior managers, medical directors, clinical-trial
managers, and project managers – receive R&D Directions 10 times per
year. For more
information, contact Fran Mehesz at 215-867-0044, ext. 211, or
fmehesz@engelpub.com.
About Engel Publishing Partners
For 25 years, Engel Publishing Partners has been the source that pharmaceutical executives turn to for the information they need to create competitive business strategies. Engel Publishing Partners carries a full product line, offering industry-leading publications, informative newsletters, and data-rich interactive products. Through these channels, Engel Publishing Partners disseminates original and un-biased content that provides insight into industry trends and events, as well as extensive analysis of companies, products, and pipelines.
###
Posted: March 2007
